Sinovac’s Hepatitis Vaccine Selected By Beijing CDC

Sinovac Biotech has received confirmation from Beijing Medicine Bidding Center that its hepatitis A vaccine Healive was selected by the Beijing Centers For Diseases Control and Prevention pursuant to its tender process.

As a result of the selection, Healive is one of two inactivated hepatitis A vaccines in pre-filled syringes that will be purchased by the Beijing Centers For Diseases Control and Prevention (Beijing CDC) for its hepatitis A vaccination program. The tender covers purchasing activities from 2007 to 2009. The selection is part of the governmental initiative to include hepatitis A in the China national expanded immunization program.

Weidong Yin, chairman, president and CEO, said: “We are pleased to receive confirmation that Healive was selected by the Beijing CDC. The tender process evaluated the safety and efficacy profile of Healive, in conjunction with Sinovac’s manufacturing capability and post-sales service in order to supply the requisite doses over the next three years.”